Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.
Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, O'Hare T, Deininger MW. Eiring AM, et al. Among authors: khorashad js. Leukemia. 2015 Dec;29(12):2328-37. doi: 10.1038/leu.2015.196. Epub 2015 Jul 23. Leukemia. 2015. PMID: 26202934 Free PMC article.
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC, de Lavallade H, Garland P, Rezvani K, Apperley JF, Goldman JM, Foroni L, Khorashad JS. Bazeos A, et al. Among authors: khorashad js. Leukemia. 2010 Jun;24(6):1243-5. doi: 10.1038/leu.2010.86. Epub 2010 May 6. Leukemia. 2010. PMID: 20445576 No abstract available.
Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.
Grant H, Jiang X, Stebbing J, Foroni L, Craddock C, Griffiths M, Clark RE, O'Brien S, Khorashad JS, Gerrard G, Wang L, Irving JA, Wang M, Karran L, Dyer MJ, Forrest D, Page K, Eaves CJ, Woolfson A. Grant H, et al. Among authors: khorashad js. Leukemia. 2010 Oct;24(10):1817-21. doi: 10.1038/leu.2010.179. Epub 2010 Aug 26. Leukemia. 2010. PMID: 20739956 No abstract available.
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. Marin D, et al. Among authors: khorashad js. Leukemia. 2012 Feb;26(2):296-302. doi: 10.1038/leu.2011.180. Epub 2011 Aug 16. Leukemia. 2012. PMID: 21844874
Advances in the treatment of chronic myeloid leukemia.
Eiring AM, Khorashad JS, Morley K, Deininger MW. Eiring AM, et al. Among authors: khorashad js. BMC Med. 2011 Aug 26;9:99. doi: 10.1186/1741-7015-9-99. BMC Med. 2011. PMID: 21867560 Free PMC article. Review.
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, O'Hare T, Deininger MW. Khorashad JS, et al. Blood. 2013 Jan 17;121(3):489-98. doi: 10.1182/blood-2012-05-431379. Epub 2012 Dec 5. Blood. 2013. PMID: 23223358 Free PMC article.
New concepts for CML clonality.
Khorashad JS, Deininger MW, O'Hare T. Khorashad JS, et al. Oncotarget. 2013 Jan;4(1):7-8. doi: 10.18632/oncotarget.882. Oncotarget. 2013. PMID: 23448894 Free PMC article. No abstract available.
73 results